MAP2K4 and hepatocellular carcinoma: Furthermore, co-treatment with LicoA and Sor resulted in significant synergistic anti-metastatic effects on human hepatocellular carcinoma via the inactivation of the MKK4/JNK pathway and the downregulation of uPA [43].